FDA grants priority review for Roche ’s Actemra/RoActemra (tocilizumab) supplemental biologics license application for giant cell arteritis, a form of vasculitis

Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental biologics license application (sBLA) for Actemra/RoActemra (tocilizumab) for the treatment of GCA, a chronic, potentially life-threatening autoimmune condition.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news